Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Tonix Pharmaceuticals Holding Corp. (TNXP)
|
Add to portfolio |
|
|
|
| Price: |
$0.37
| | Metrics |
| OS: |
17.8
|
M
| |
-89
|
% ROE
|
| Market cap: |
$6.64
|
M
| |
-112
|
% ROIC
|
|
Net cash:
|
$25.6
|
M
| |
$1.44
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($122)
|
M
| |
|
|
|
EBIT
|
($125)
|
M
| |
|
|
| EPS |
($4.84)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | | | | | | | |
| Research and development | 81.9 | 68.8 | 36.2 | 18.2 | 17.6 | 13.3 | 28.5 | 35.5 |
| General and administrative | 30.2 | 23.5 | 14.4 | 10.6 | 8.8 | 7.9 | 10.4 | 12.7 |
| EBIT | -112.1 | -92.3 | -50.5 | -28.8 | -26.3 | -21.3 | -39.0 | -48.2 |
| EBIT margin | | | | | | | | |
| Pre-tax income | -110.2 | -92.3 | -50.5 | -28.6 | -26.1 | -21.1 | -38.8 | -48.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -116.9 | -92.3 | -52.2 | -31.1 | -29.4 | -21.1 | -38.8 | -48.1 |
| Net margin | | | | | | | | |
| |
| Diluted EPS | ($3.27) | ($8.10) | ($0.55) | ($19.33) | ($259.85) | ($31.69) | ($15.41) | ($28.62) |
| Shares outstanding (diluted) | 35.7 | 11.4 | 94.6 | 1.6 | 0.1 | 0.7 | 2.5 | 1.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|